Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51024 | 0.75 | MEN1 (0.69) | MEN1KMT2ATAAR1 | |
| SCHEMBL859158 | 0.74 | RAB9A (0.52) | MEN1KMT2A | |
| SCHEMBL13423728 | 0.72 | MEN1 (0.53) | DRD4MEN1KMT2ASIGMAR1CYP1A2 | |
| SCHEMBL11358847 | 0.72 | SLC6A2 (0.47) | DRD4MEN1KMT2A | |
| SCHEMBL15683024 | 0.72 | DRD4 (0.49) | DRD4MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL21858962 | 0.70 | MEN1 (0.43) | DRD4MEN1KMT2ASIGMAR1CYP3A4 | |
| SCHEMBL51135 | 0.70 | MEN1 (0.67) | MEN1KMT2ATAAR1 | |
| SCHEMBL10750642 | 0.69 | SMN1; SMN2 (0.46) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL10487984 | 0.68 | MEN1 (0.65) | MEN1KMT2ASIGMAR1TAAR1 | |
| SCHEMBL9136546 | 0.68 | MEN1 (0.65) | MEN1KMT2ASIGMAR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018229-B2 | Organic compounds | GIVAUDAN SA (CH) | 2024-06-25 | — | — | US | disclosed |
| US-20210355411-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2021-11-18 | — | — | US | disclosed |
| WO-2020079052-A1 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355411-A1 | ORGANIC COMPOUNDS | TRPA1, DHODH, QDPR | DRD4 76/4885MEN1 4078/4885KMT2A 2866/4885 |
| US-12018229-B2 | Organic compounds | TRPA1, DHODH, QDPR | DRD4 76/4885MEN1 4078/4885KMT2A 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.